Targeted oncolytic herpes simplex viruses for aggressive cancers.

Area of Science:

• Oncolytic virotherapy
• Gene therapy
• Cancer research

Background:

• Herpes simplex virus (HSV) is a promising vector for cancer gene therapy due to its oncolytic properties.
• Traditional HSV designs (e.g., G207) involve gene deletion for tumor specificity, often resulting in reduced viral efficacy.
• Tumor microenvironments present challenges for virus dissemination and efficacy.

Purpose of the Study:

• To review advancements in oncolytic HSV engineering, focusing on novel designs that do not require viral gene deletion.
• To compare the efficacy and tumor specificity of newer transcriptional translational dually regulated HSV (TTDR-HSV) with classical defective HSV designs.
• To discuss challenges posed by aggressive tumor heterogeneity and volatility for oncolytic virus therapy.

Main Methods:

• Review of existing literature on HSV-based oncolytic therapies.
• Comparison of gene-deleted HSV (e.g., G207, tk- HSV) with non-gene-deleted TTDR-HSV designs.
• Analysis of tumor cellular features impacting oncolytic virus dissemination.

Main Results:

• Non-gene-deleted HSV designs, such as TTDR-HSV, aim to maximize viral replication and oncolytic potential.
• TTDR-HSV demonstrates tumor specificity without the marked attenuation seen in gene-deleted counterparts.
• Tumor heterogeneity and volatility remain significant hurdles for effective oncolytic virus delivery and action.

Conclusions:

• Novel TTDR-HSV designs represent an improvement over classical defective HSV vectors by preserving viral replication capacity.
• Further research is needed to optimize TTDR-HSV for targeting heterogeneous and dynamic aggressive tumors.
• Combinatorial strategies may be necessary to enhance the effectiveness of TTDR-HSV in complex tumor microenvironments.